Celgene bags CAR-T player Juno in $9B buyout as biotech M&A suddenly explodes
The buyout buzz was accurate.
Celgene $CELG has struck a deal to buy Juno Therapeutics $JUNO for $87 a share, or about $9 billion, instantly vaulting into the front ranks of the CAR-T companies. And they plan to stay there, vowing to become the preeminent player in one of the most competitive R&D rivalries in the industry.
Celgene stamped the deal with its own bullish forecast that the buyout will quickly deliver a new CAR-T that will hit peak sales of $3 billion a year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.